T T

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/765,466	01/26/2004	Sachiko Machida	690115.401C1	8356
500 759 SEED INTELLEO	02/07/2007 CTUAL PROPERTY L	EXAMINER		
701 FIFTH AVE		YU, MELANIE J		
SUITE 5400 SEATTLE, WA 98104			ART UNIT	PAPER NUMBER
			1641	
SHORTENED STATUTORY P	ERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE	
3 MONTHS 02/07/2007		02/07/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

		Application No.	Applicant(s)			
		10/765,466	MACHIDA ET AL.			
	Office Action Summary	Examiner	Art Unit			
		Melanie Yu	1641			
Period fo	The MAILING DATE of this communication app or Reply	ears on the cover sheet with t	he correspondence address			
A SH WHIC - Exte after - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR REPLY CHEVER IS LONGER, FROM THE MAILING DAMES OF THE MAILING DAMES OF THE MORE OF TH	ATE OF THIS COMMUNICAT 36(a). In no event, however, may a reply vill apply and will expire SIX (6) MONTHS , cause the application to become ABAND	FION. be timely filed from the mailing date of this communication. FONED (35 U.S.C. § 133).			
Status	•					
1)⊠	Responsive to communication(s) filed on 02 No	ovember 2006.	•			
2a) <u></u> ☐	This action is FINAL . 2b)⊠ This action is non-final.					
3)	 · · · · · · · · · · · · · · · · · ·					
	closed in accordance with the practice under E	x parte Quayle, 1935 C.D. 11	I, 453 O.G. 213.			
Disposit	ion of Claims					
5)□ 6)⊠ 7)□	Claim(s) 1,15-17,44 and 45 is/are pending in the 4a) Of the above claim(s) is/are withdraw Claim(s) is/are allowed. Claim(s) 1,15-17,44 and 45 is/are rejected. Claim(s) is/are objected to. Claim(s) are subject to restriction and/or	vn from consideration.				
Applicat	ion Papers					
9)□ 10)⊠	The specification is objected to by the Examine The drawing(s) filed on <u>26 January 2004</u> is/are: Applicant may not request that any objection to the Replacement drawing sheet(s) including the correction The oath or declaration is objected to by the Examine	a)⊠ accepted or b)□ object drawing(s) be held in abeyance. ion is required if the drawing(s) i	See 37 CFR 1.85(a). s objected to. See 37 CFR 1.121(d).			
Priority (under 35 U.S.C. § 119	•				
a)	Acknowledgment is made of a claim for foreign All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the priority application from the International Bureau See the attached detailed Office action for a list	s have been received. s have been received in Appli rity documents have been rec ı (PCT Rule 17.2(a)).	ication No eived in this National Stage			
	ce of References Cited (PTO-892)		mary (PTO-413)			
3) 🔲 Infor	ce of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO/SB/08) er No(s)/Mail Date		ail Date nal Patent Application			

Application/Control Number: 10/765,466

Art Unit: 1641

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 2 November 2006 has been entered.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

The factual inquiries set forth in Graham v. John Deere Co., 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

- 1. Determining the scope and contents of the prior art.
- 2. Ascertaining the differences between the prior art and the claims at issue.
- 3. Resolving the level of ordinary skill in the pertinent art.
- 4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
- 2. Claim 1 is rejected under 35 U.S.C. 103(a) as being unpatentable over Holtzman (US 5,969,123) in view of Schatz (US 5,932,433).

Holtzman teaches a biochip for a screening assay (col. 12, lines 7-8) comprising a biotinylated receptor protein immobilized via a factor capable of specifically binding to biotin (streptavidin specifically binds to biotin and the biotinylated proteins is immobilized to the

Page 2

Page 3

Art Unit: 1641

streptavidin, col. 12, lines 8-16), wherein the receptor protein comprises a biotinylation sequence motif (biotinylated protein comprises biotinylation sequence motif, col. 12, lines 11-16), and wherein the receptor protein has the ability of being specifically bound by a ligand of the receptor protein (col. 8, line 65-col. 9, line 6). Holtzman fails to teach the biotinylation of the receptor protein carried out within a bacterial host.

Schatz teaches a recombinantly expressed biotinylated receptor protein immobilized via a factor capable of specifically binding to biotin (peptides are biotinylated and bound to streptavidin which specifically binds to biotin, col. 8, lines 10-27, biotinylated peptide may be a protein, col. 6, lines 13-19), wherein the receptor protein comprises a biotinylation sequence motif (when peptides are biotinylated, they gain a biotinylation sequence motif, col. 8, lines 10-27; col. 4, lines 57-60), wherein the biotinylation of the receptor protein has been carried out within a bacterial host instead of in vitro (carried out in *E. coli* host cells, col. 3, lines 47-50; col. 8, lines 10-14), in order to provide a protein that has been biotinylated.

Therefore it would have been obvious to one having ordinary skill in the art at the time the invention was made to include in the biotinylation of the receptor protein of Holtzman, biotinylation in vivo instead of in vitro as taught by Schatz, in order to provide a simplified biotinylation process (Schatz, col. 2, lines 59-63).

3. Claims 15 and 16 are rejected under 35 U.S.C. 103(a) as being unpatentable over Holtzman (US 5,969,123) in view of Schatz (US 5,932,433) further in view of Tall et al. (US 6,756,228).

Holtzman in view of Schatz teach a biotinylated receptor protein that is immobilized to a substrate via a factor capable of specifically binding to biotin, but fail to teach the receptor specifically being LOX-1.

Application/Control Number: 10/765,466

Art Unit: 1641

Tall et al. teach a LOX-1 receptor immobilized to a substrate (col. 12, lines 29-38; col. 11, line 52-col. 12, line 57), in order to detect the presence of LOX-1 activity.

Therefore it would have been obvious to one having ordinary skill in the art at the time the invention was made to include as the receptor protein of Holtzman in view of Schatz, a receptor protein of LOX-1 as taught by Tall et al., in order to provide a substrate that indicates a decreased or increased susceptibility to atherosclerosis.

4. Claims 17 and 44 are rejected under 35 U.S.C. 103(a) as being unpatentable over Brigham-Burke et al. (US 5,395,587) in view of Holtzman (US 5,969,123) further in view of Schatz (US 5,932,433).

Brigham-Burke et al. teach a protein immobilized on a SPR substrate (sensor chip, col. 5, lines 29-35; col. 5, lines 10-23) that conforms to a shape of an insertion site of a surface plasmon resonance device (sensor chip fits through a slot in the housing for SPR detection, 14, Fig. 1; col. 5, lines 30-35), but fail to teach the protein being biotinylated and immobilized via a factor capable of binding specifically to biotin.

Holtzman in view of Schatz, as applied to claim 1, teach a biotinylated receptor protein immobilized on a substrate via a factor capable of specifically binding to biotin, in order to provide immobilization of receptor proteins on a substrate.

Therefore it would have been obvious to one having ordinary skill in the art at the time the invention was made to include on the substrate of Brigham-Burke et al., an immobilization technique of a biotinylated receptor protein as taught by Holtzman in view of Schatz, in order to simple and efficient immobilization of proteins on a substrate.

5. Claims 17 and 45 are rejected under 35 U.S.C. 103(a) as being unpatentable over Muramatsu (Piezoelectric Crystal Biosensor Modified with Protein A for Determination of Immunoglobulins, 1987, Analytical Chemistry, vol. 59, pages 2760-2763) in view of Holtzman (US 5,969,123) further in view of Schatz (US 5,932,433).

Art Unit: 1641

Muramatsu teaches a protein immobilized on a crystal oscillator (pg. 2760, right column, last paragraph), but fail to teach the protein being biotinylated and immobilized via a factor capable of binding specifically to biotin.

Holtzman in view of Schatz, as applied to claim 1, teach a biotinylated receptor protein immobilized on a substrate via a factor capable of specifically binding to biotin, in order to provide immobilization of receptor proteins on a substrate.

Therefore it would have been obvious to one having ordinary skill in the art at the time the invention was made to include on the substrate of Muramatsu, biotinylation of a protein receptor and immobilization via a factor capable of binding specifically to biotin as taught by Holtzman in view of Schatz, in order to simple and efficient immobilization of proteins on a substrate.

Response to Arguments

6. Applicant's arguments with respect to claims 1, 15-17, 44 and 45 have been considered but are moot in view of the new ground(s) of rejection. The previous rejections of the claims have been withdrawn. Therefore, the rejection has been withdrawn. However, upon further consideration, a new ground(s) of rejection is made in view of applicant's amendment requiring a biotinylation sequence motif.

Conclusion

No claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Melanie Yu whose telephone number is (571) 272-2933. The examiner can normally be reached on M-F 8:30-5.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Long Le can be reached on (571) 272-0823. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/765,466 Page 6

Art Unit: 1641

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Melanie Yu Patent Examiner Art Unit 1641

Milantip

LONG V. LE ~2/01/07 SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600